Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares
Mandate

Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares

June 09, 2011

BioInvent International AB (publ) (NASDAQ OMX Stockholm) has completed a private placement of new shares with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure. Carnegie Investment Bank and Kempen & Co acted as Joint Global Co-ordinators and Joint Bookrunners.

Vinge and Latham & Watkins were legal advisors to the bookrunners. The Vinge team was headed by capital markets partner Erik Sjöman.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024